PARD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PARD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Poniard Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2011 was 0.00.
The historical rank and industry rank for Poniard Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Poniard Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Poniard Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Poniard Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Poniard Pharmaceuticals (OTCPK:PARD) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Poniard Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S Perry | officer: President & CMO | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Ron Martell | director, officer: Chief Executive Officer | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
David R Stevens | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Fred B Craves | director | 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111 |
Simon Nicholas J Iii | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Gregory L Weaver | officer: Chief Financial Officer | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
Kurt Wheeler | 10 percent owner | 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080 |
Mpm Asset Management Investors 2005 Bviii Llc | 10 percent owner | C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199 |
Nicholas Galakatos | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Dennis Henner | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Michael Steinmetz | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Luke Evnin | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
From GuruFocus
By gurufocus • 04-06-2009
By GuruFocus Research GuruFocus Editor • 08-22-2009
By gurufocus • 05-12-2009
By gurufocus 10qk • 08-09-2010
By gurufocus • 08-07-2009
By gurufocus 10qk • 11-09-2010
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 11-06-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.